<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methenamine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methenamine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methenamine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9626" href="/d/html/9626.html" rel="external">see "Methenamine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12076" href="/d/html/12076.html" rel="external">see "Methenamine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F194204"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Hiprex</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1048556"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F194220"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Urine pH should be acidic (eg, pH &lt;5.5) for optimal efficacy. <b></b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="541bf6e1-573d-4f15-b63c-6b65f37fda55">Urinary tract infection, prophylaxis/suppression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urinary tract infection, prophylaxis/suppression:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Methenamine hippurate:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 12 years: Oral: 500 to 1,000 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 1,000 mg twice daily</p>
<p style="text-indent:-2em;margin-left:4em;">Methenamine mandelate:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;6 years: Oral: 50 to 75 mg/kg/day divided every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>); maximum dose: 500 mg/dose</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to 12 years: Oral: 500 mg 4 times daily</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 1,000 mg 4 times daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129909"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: Use is contraindicated.</p></div>
<div class="block dohp drugH1Div" id="F51129910"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doa drugH1Div" id="F194208"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9626" href="/d/html/9626.html" rel="external">see "Methenamine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88aac08e-f00f-4b29-bf1c-0e7015eed55f">Urinary tract infection, prophylaxis for recurrent infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Urinary tract infection, prophylaxis for recurrent infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be considered in patients with bothersome, frequently recurrent cystitis despite other nonantimicrobial preventative measures. The optimal duration has not been established; up to 12 months has been studied with periodic reassessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35264408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35264408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hippurate: <b>Oral:</b> 1 g twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Mandelate: <b>Oral:</b> 1 g four times daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991829"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Limited data is available in patients with renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11869659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11869659'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Mild to severe impairment: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50989115"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F194173"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (&lt;4%), nausea (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (Harding 2022), abdominal pain (Harding 2022), diarrhea (Harding 2022), vomiting (Harding 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (Harding 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (Harding 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (Harding 2022)</p></div>
<div class="block coi drugH1Div" id="F194187"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to methenamine or any component of the formulation; severe dehydration; renal impairment; severe hepatic impairment; concurrent treatment with sulfonamides</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F194170"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: Avoid use in patients with gout; may precipitate urate crystals in urine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; reversible increases in liver function tests have occurred during therapy; periodically monitor liver function, especially in patients with hepatic impairment. Contraindicated in patients with severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in certain individuals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Use only when long-term therapy is indicated and infection has been eradicated by appropriate antimicrobial treatment. Should not be used to treat infections outside of the lower urinary tract. Doses of 8 g daily for 3 to 4 weeks may cause bladder irritation, painful and frequent micturition, albuminuria, and gross hematuria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary acidification: Use care to maintain an acid pH of the urine, especially when treating infections due to urea splitting organisms (eg, <i>Proteus</i> and strains of <i>Pseudomonas</i>); when urine acidification is contraindicated or unattainable, use is not recommended.</p></div>
<div class="block foc drugH1Div" id="F194182"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hiprex: 1 g [scored; contains fd&amp;c yellow #5 (tartrazine), saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 g, 1 g</p></div>
<div class="block geq drugH1Div" id="F194166"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F194190"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Hiprex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $2.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methenamine Hippurate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $2.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Methenamine Mandelate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 g (per each): $0.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $1.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613279"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food to minimize GI upset; patient should drink plenty of fluids to ensure adequate urine flow; administer with cranberry juice, ascorbic acid, or ammonium chloride to acidify urine; avoid intake of alkalinizing agents (sodium bicarbonate, antacids)</p></div>
<div class="block adm drugH1Div" id="F803168"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Restrict alkalinizing foods and medications to maintain urine pH ≤5.5.</p>
<p style="text-indent:-2em;margin-left:2em;">Hippurate: Administer twice daily (morning and night).</p>
<p style="text-indent:-2em;margin-left:2em;">Mandelate: Administer 4 times daily (after each meal and at bedtime).</p></div>
<div class="block sts drugH1Div" id="F194199"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53567772"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis or suppression of recurrent urinary tract infections (Hippurate: FDA approved in ages ≥6 years and adults; Mandelate: FDA approved in children, adolescents, and adults)</p></div>
<div class="block mst drugH1Div" id="F194234"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Hiprex may be confused with Mirapex</p>
<p style="text-indent:-2em;margin-left:4em;">Methenamine may be confused with mesalamine, methazolAMIDE, methionine</p>
<p style="text-indent:-2em;margin-left:4em;">Urex may be confused with Eurax, Serax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Urex: Brand name for methenamine [US (discontinued)], but also the brand name for furosemide [Australia, China, Turkey]</p>
<p style="text-indent:-2em;margin-left:4em;">Urex [US. (discontinued)] may be confused with Eurax brand name for crotamitin [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299683"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F194175"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Urinary Acidifying Agents may decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Urinary Acidifying Agents may decrease the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as antacids, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding the concomitant use of medications that alkalinize the urine, such as carbonic anhydrase inhibitors, and methenamine. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: Urinary Acidifying Agents may increase the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Urinary Acidifying Agents may decrease the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfaSALAzine: Methenamine may enhance the adverse/toxic effect of SulfaSALAzine. Specifically, the combination may result in the formation of an insoluble precipitate in the urine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: Methenamine may enhance the adverse/toxic effect of Sulfonamide Antibiotics. Specifically, the combination may result in the formation of an insoluble precipitate in the urine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Methenamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Uva Ursi: Urinary Acidifying Agents may diminish the therapeutic effect of Uva Ursi.  Management: Consider avoiding use of uva ursi with agents that acidify the urine, as this may impair uva ursi efficacy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F194200"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Foods/diets which alkalinize urine (pH &gt;5.5) decrease therapeutic effect of methenamine.</p></div>
<div class="block dic drugH1Div" id="F194193"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Foods/diets that alkalinize urine pH &gt;5.5 decrease activity of methenamine. Some products may contain tartrazine.</p></div>
<div class="block pri drugH1Div" id="F194191"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methenamine crosses the placenta and distributes to amniotic fluid (Allgén 1979). An increased risk of adverse fetal effects has not been observed in available studies (Furness 1975; Gordon 1972; Heinonen 1977). Methenamine use has been shown to interfere with urine estriol concentrations if measured via acid hydrolysis. Use of enzyme hydrolysis prevents this lab interference.</p></div>
<div class="block mopp drugH1Div" id="F53567768"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Urinary pH, urinalysis, urine cultures, periodic liver function tests in patients receiving hippurate salt</p></div>
<div class="block pha drugH1Div" id="F194169"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Methenamine is hydrolyzed to formaldehyde and ammonia in acidic urine; formaldehyde has nonspecific bactericidal action. Other components, hippuric acid or mandelic acid, aid in maintaining urine acidity and may aid in suppressing bacteria.</p></div>
<div class="block phk drugH1Div" id="F194186"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Readily from the GI tract; 10% to 30% of the drug will be hydrolyzed by gastric juices unless it is protected by an enteric coating </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 0.6 L/kg (Allgén 1979)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hydrolyzed to formaldehyde and ammonia in the urine; ~10% to 25% in the liver </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~4 hours (Allgén 1979)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 1 to 2 hours (Allgén 1979)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~70% to 90% as unchanged drug) within 24 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F194194"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Hiprex | Uropurat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hiprex | Uramet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hexacitrol | Hexamin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mandelamine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hexamine | Methenamine | Urotropine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Urobejar | Urofrancol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Hipeksal | Hippuran | Hiprex | Mandeheksan | Merapan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Urotropine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Hexamine | Hiprex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mandelamin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Hexamine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Uronamin sumitomo</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mandecin | Mendalamin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hexacitrol | Hexamin | Urobesal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hexacitrol | Hexamin | Urobesal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Mandelamine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bioran | Hiprex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Methenamine-amygdalaat | Methenamine-amygdalaat CF | Reflux</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Hiprex | Methenamine hippurate eql pharma</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hexamine hippurate | Hiprex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Hexamandin | Mandehexan | Mandelamina | Mandelamine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Hiprex | Mandelamine | Uretron ds | Urex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hiprex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Mandelamine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Hippurin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mandelamine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Hippramine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-484222">
<a name="484222"></a>Allgén LG, Holmberg G, Persson B, et al. Biological Fate of Methenamine in Man. Absorption, Renal Excretion and Passage to Umbilical Cord Blood, Amniotic Fluid and Breast Milk. <i>Acta Obstet Gynecol Scand</i>. 1979;58(3):287-293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/484222/pubmed" id="484222" target="_blank">484222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Overtuf GD, Prober DC, eds. <i>Red Book: 2003 Report of the Committee on Infectious Diseases</i>. 26th ed. American Academy of Pediatrics; 2003.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1099490">
<a name="1099490"></a>Furness ET, McDonald PJ, Beasley NV. Urinary Antiseptics in Asymptomatic Bacteriuria of Pregnancy. <i>N Z Med J</i>. 1975;81(539):417-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/1099490/pubmed" id="1099490" target="_blank">1099490</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gordon SF. Asymptomatic Bacteriuria of Pregnancy. <i>Clinical Medicine</i>. 1972:22-24.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35264408">
<a name="35264408"></a>Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. <i>BMJ</i>. 2022;376:e068229. doi:10.1136/bmj-2021-0068229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/35264408/pubmed" id="35264408" target="_blank">35264408</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Heinonen OP, Slone D, Shapiro S. <i>Birth Defects and Drugs in Pregnancy</i>. Publishing Sciences Group Inc; 1977.</div>
</li>
<li>
<div class="reference">
                  Hiprex (methenamine) [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20175247">
<a name="20175247"></a>Hooton TM, Bradley SF, Cardenas DD, et al; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(5):625-663.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/20175247/pubmed" id="20175247" target="_blank">20175247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11869659">
<a name="11869659"></a>Lee B, Bhuta T, Craig J, Simpson J. Methenamine hippurate for preventing urinary tract infections. <i>Cochrane Database Syst Rev</i>. 2002;(1):CD003265. doi:10.1002/14651858.CD003265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methenamine-pediatric-drug-information/abstract-text/11869659/pubmed" id="11869659" target="_blank">11869659</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Methenamine mandelate [prescribing information]. Congers, NY: Chartwell Rx LLC; September 2021.</div>
</li>
<li>
<div class="reference">
                  Urex tablets (methenamine) [prescribing information]. Wytheville VA: Vatring Pharmaceuticals Inc; December 2006.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12591 Version 225.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
